Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTICCA-1 adjuvant gemcitabine + cisplatin versus capecitabine after resection of biliary tract cancer
NL-OMON53034Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Gemcitabine + cisplatin with Capecitabine (2 arms). Primary endpoint: Disease-free survival. Started Sep 2015; status: recruiting.
02
Drugs
gemcitabinecisplatincapecitabine
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NL-OMON53034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53034.